ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 22 2025
0mins
Should l Buy ?
Source: Globenewswire
Clinical Trial Results: Firmonertinib shows a median progression-free survival of 16 months in first-line patients with EGFR PACC mutant non-small cell lung cancer (NSCLC), along with significant central nervous system activity and a favorable safety profile.
Future Developments: ArriVent plans to initiate a pivotal Phase 3 trial (ALPACCA) for firmonertinib in the second half of 2025, aiming for accelerated approval based on promising interim data from ongoing studies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
